Adaptive Biotechnologies (ADPT) Cost of Revenue (2018 - 2026)

Adaptive Biotechnologies has reported Cost of Revenue for 9 years, with the latest figure at $18.7 million in Q1 2026.

• Quarterly Cost of Revenue rose 10.18% year-over-year to $18.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.1 million (up 2.93% YoY) and the FY2025 annual result came in at $71.4 million, down 1.0% from the prior year.
• Cost of Revenue climbed to $18.7 million in Q1 2026 per ADPT's latest filing, from $18.2 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $19.6 million in Q4 2023 and troughed at $13.2 million in Q1 2022.
• A 5-year average of $17.4 million and a median of $18.0 million in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2023 and 2024: Cost of Revenue surged 41.61% in 2023, then slipped 13.85% in 2024.
• Over 5 years, Cost of Revenue stood at $16.6 million in 2022, then rose by 18.25% to $19.6 million in 2023, then retreated by 8.01% to $18.0 million in 2024, then climbed by 0.99% to $18.2 million in 2025, then rose by 2.66% to $18.7 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $18.7 million, $18.2 million, and $18.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.